Third Biosimilar Launches in the United States

The biosimilar infliximab-abda (Renflexis) is now being commercialized in the United States following its April 2017 FDA approval.
Infliximab-abda is a tumor necrosis factor (TNF) blocker and is a biosimilar referencing infliximab (Remicade), according to a press release. It is indicated to treat Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
The biosimilar will be priced at a wholesale acquisition cost of USD $753.39, a 35% reduction to the current wholesale acquisition cost of infliximab.
“Since we were established 5 years ago, we have strived to bring high-quality treatment options at a lower cost to US patients,” Christopher Hansung Ko, president and CEO of Samsung Bioepis, said in a release. “Renflexis is our first step in meeting this important commitment. We firmly believe biosimilars will play an instrumental role in making health care more accessible to patients across the US, and we will continue our relentless drive to advance one of the industry’s strongest pipelines.”
Infliximab-abda is Samsung Bioepis’ first drug to launch in the United States, according to the release.
Biosimilars are heralded as an affordable alternative to expensive biologic medications. Although they show significant potential to reduce the overall cost of treatment, prescriber uptake has been slow largely due to the current reimbursement model. 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

The New Drug Application for upadacitinib is supported by data from the phase 3 SELECT trial program evaluating patients with moderate-to-severe rheumatoid arthritis.
Data from an analysis of multiple phase 3 studies highlight improvements in mobility, self-care, and usual activities for patients with moderate-to-severe psoriasis taking secukinumab (Cosentyx).
Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses the need for increased pharmacy benefit manager regulation on a federal level.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.